Volume 87, Issue 2 pp. 267-280
Research Article

Evolution of anosognosia in alzheimer's disease and its relationship to amyloid

Bernard J. Hanseeuw MD, PhD

Bernard J. Hanseeuw MD, PhD

Department of Neurology, Cliniques Universitaires Saint-Luc, and Institute of Neuroscience, Catholic University of Louvain, Brussels, Belgium

Department of Neurology and Radiology, Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA

B.J.H. and M.R.S. contributed equally to this work.Search for more papers by this author
Matthew R. Scott BA

Matthew R. Scott BA

Department of Neurology and Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA

B.J.H. and M.R.S. contributed equally to this work.Search for more papers by this author
Sietske A. M. Sikkes PhD

Sietske A. M. Sikkes PhD

Department of Neurology and Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Department of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Center, VU University, Amsterdam, the Netherlands

Search for more papers by this author
Michael Properzi BEng

Michael Properzi BEng

Department of Neurology and Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Search for more papers by this author
Jennifer R. Gatchel MD, PhD

Jennifer R. Gatchel MD, PhD

Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Division of Geriatric Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA

Search for more papers by this author
Eric Salmon MD, PhD

Eric Salmon MD, PhD

GIGA Cyclotron Research Center-IVI, University of Liege, Quartier Agora, Sart Tilman, Belgium

Search for more papers by this author
Gad A. Marshall MD

Gad A. Marshall MD

Department of Neurology and Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Search for more papers by this author
Patrizia Vannini MD

Corresponding Author

Patrizia Vannini MD

Department of Neurology and Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Address correspondence to Dr Vannini, PhD, Massachusetts General Hospital, 149 13th Street, Suite 10.042, Charlestown, MA 02129. E-mail: [email protected]Search for more papers by this author
Alzheimer's Disease Neuroimaging Initiative

Alzheimer's Disease Neuroimaging Initiative

Search for more papers by this author
First published: 21 November 2019
Citations: 49
Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of the ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
Correction added on December 11, 2019, after first online publication: “Alzheimer disease” has been changed to “Alzheimer's disease” in the title and throughout the article.

Abstract

Objective

Unawareness, or anosognosia, of memory deficits is a challenging manifestation of Alzheimer's disease (AD) that adversely affects a patient's safety and decision-making. However, there is a lack of consensus regarding the presence, as well as the evolution, of altered awareness of memory function across the preclinical and prodromal stages of AD. Here, we aimed to characterize change in awareness of memory abilities and its relationship to beta-amyloid (Aβ) burden in a large cohort (N = 1,070) of individuals across the disease spectrum.

Methods

Memory awareness was longitudinally assessed (average number of visits = 4.3) and operationalized using the discrepancy between mean participant and partner report on the Everyday Cognition scale (memory domain). Aβ deposition was measured at baseline using [18F]florbetapir positron emission tomographic imaging.

Results

Aβ predicted longitudinal changes in memory awareness, such that awareness decreased faster in participants with increased Aβ burden. Aβ and clinical group interacted to predict change in memory awareness, demonstrating the strongest effect in dementia participants, but could also be found in the cognitively normal (CN) participants. In a subset of CN participants who progressed to mild cognitive impairment (MCI), heightened memory awareness was observed up to 1.6 years before MCI diagnosis, with memory awareness declining until the time of progression to MCI (−0.08 discrepant-points/yr). In a subset of MCI participants who progressed to dementia, awareness was low initially and continued to decline (−0.23 discrepant-points/yr), reaching anosognosia 3.2 years before dementia onset.

Interpretation

Aβ burden is associated with a progressive decrease in self-awareness of memory deficits, reaching anosognosia approximately 3 years before dementia diagnosis. ANN NEUROL 2020;87:267–280

Potential Conflicts of Interest

None.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

click me